We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

STANDARD DIAGNOSTICS INC.

Standard Diagnostics develops rapid diagnostic tests that make it possible to diagnose various diseases at an earlier... read more Featured Products: More products

Download Mobile App




Malaria Parasite Evades Rapid Test Detection in Children

By LabMedica International staff writers
Posted on 30 Nov 2016
Rapid diagnostic tests account for more than 70% of diagnostic testing for malaria in Africa and most rapid test diagnostics rely on the detection an antigen specific to Plasmodium falciparum malaria.

The Democratic Republic of the Congo (DRC) has one of the highest rates of people living with malaria. More...
Most rapid test diagnostics (RDT) rely on the detection of histidine-rich protein 2 (HRP2), an antigen specific to P. falciparum malaria. However, one of every 15 children infected with P. falciparum malaria parasites in the DRC is infected by a pfhrp2-deleted mutant, producing a false-negative result when an RDT is used.

An international team of scientists led by those at University of North Carolina Health Care System (Chapel Hill, NC, USA) collected samples from children under five years of age as part of the 2013- 2014 DRC Demographic and Health Survey. The majority of children were asymptomatic at the time of sample collection. Heel- or finger-prick blood from each participant was analyzed by light microscopy for parasites, applied to an RDT targeting the P. falciparum HRP2 antigen.

The samples were applied to an RDT targeting the P. falciparum HRP2 antigen (SD BIOLINE Malaria Ag P.f., Standard Diagnostics, Gyeonggi-do, Republic of Korea), and used to prepare dried blood spots (DBS). Three diagnostic methods were performed for each child: RDT, microscopy, and polymerase chain reaction (PCR). The real-time PCR assay with a limit of detection of 100 parasites/μL was employed to identify P. falciparum infection by amplifying a region of the single-copy pfldh gene.

The team focused on 783 samples with opposing rapid test diagnostic test and polymerase chain reaction (PCR) results. PCR testing showed positive results for malaria where rapid diagnostic testing did not. They identified 149 pfhrp2-deleted parasites, representing 6.4% of all P. falciparum infections country-wide among the 2,752 children diagnosed with P. falciparum infection by real-time PCR and 19.0 % of the 783 RDT-/PCR+ parasites tested.

Jonathan Parr, MD. MPH. the study's lead author, said, “This is the first nationwide study to demonstrate the presence and estimate the prevalence of malaria caused by pfhrp2-deleted P. falciparum in asymptomatic children. Because most rapid diagnostic tests in the DRC are HRP2-based, they will fail to detect these parasites. Their spread would represent a serious threat to malaria elimination efforts.” The study was published on November 14, 2016, in the Journal of Infectious Diseases.

Related Links:
University of North Carolina Health Care System
Standard Diagnostics

New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.